Abiopharma

🔍 Watson David O. (Executive)

Company: Apellis Pharmaceuticals, Inc. (APLS)

Report Date: 2026-01-07

Detailed Transactions and Holdings:

• Acquired 888 shares of Common Stock at $14.95 per share (Direct)
  Date: 2026-01-07 | Code: M | equity_swap_involved: 0 | shares_owned_after: 104,618.00 | transaction_form_type: 4
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-07 | Code: H | nature_of_ownership: Indirect Owner (Custodial Account for minor children) | shares_owned_after: 10,000.00 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-07 | Code: H | nature_of_ownership: Indirect Owner (The David O. Watson Irrevocable Trust of 2023) | shares_owned_after: 50,136.00 | Footnotes: F2
• Sold 888 shares of Stock Option (Right to Buy) at $14.95 per share (Derivative)
  Date: 2026-01-07 | Code: M | Expires: 2028-02-15 | equity_swap_involved: 0 | shares_owned_after: 14,000.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: This represents a custodial account held by the reporting person for the sole benefit of his minor children.
• F2: The securities are held by The David O. Watson Irrevocable Trust of 2023. William Zorn is the trustee of The David O. Watson Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The David O. Watson Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.
• F3: This option was granted on February 16, 2018 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.